May 2020, Drugs Monitor, Page 4

(07 May 2020) Lopinavir/Ritonavir- no benefit was observed with lopinavir–ritonavir treatment beyond standard care

May 7, 2020

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 https://www.nejm.org/doi/full/10.1056/NEJMoa2001282?query=featured_coronavirus In a randomized, controlled, open-label trial of 199 patients with laboratory-confirmed SARS-CoV-2 infection; 99 were assigned to the lopinavir–ritonavir group, and 100 to the standard-care group. Treatment with lopinavir–ritonavir… Continue reading "(07 May 2020) Lopinavir/Ritonavir- no benefit was observed with lopinavir–ritonavir treatment beyond standard care"

(07 May 2020) Hydroxychloroquine- no significant difference between hydroxychloroquine and standard care

May 7, 2020

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 https://www.nejm.org/doi/full/10.1056/NEJMoa2012410 Of the 1376 patients, 811 (58.9%) received hydroxychloroquine (600 mg twice on day 1, then 400 mg daily for a median of 5 days). Overall, 346 patients (25.1%) had a… Continue reading "(07 May 2020) Hydroxychloroquine- no significant difference between hydroxychloroquine and standard care"

(04 May 2020) Human Type I Interferons – reduced viral titers by 3.4 log in preclinical studies

May 6, 2020

Antiviral Activities of Type I Interferons to SARS-CoV-2 Infection https://doi.org/10.1016/j.antiviral.2020.104811 The sensitivity of SARS-CoV-2 to recombinant human interferons α and β (IFNα/β) is reported. Treatment with IFN-α or IFN-β at a concentration of 50 international units (IU) per milliliter reduces… Continue reading "(04 May 2020) Human Type I Interferons – reduced viral titers by 3.4 log in preclinical studies"

(04 May 2020) Chloroquine- potential to shorten the time to SARS-CoV-2 viral suppression

May 6, 2020

Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19 https://doi.org/10.1101/2020.04.26.20081059 In a multicenter prospective observational study, a total of 197 patients completed chloroquine treatment. The median time to achieve… Continue reading "(04 May 2020) Chloroquine- potential to shorten the time to SARS-CoV-2 viral suppression"

(04 May 2020) Tocilizumab- reduced effects of Tocilizumab in hyperglycemic patients

May 5, 2020

Negative impact of hyperglycemia on Tocilizumab therapy in COVID-19 patients https://www.medrxiv.org/content/10.1101/2020.04.29.20076570v1 During a retrospective study on 475 Covid-19 positive patients, 78 patients with pneumonia disease and treated with tocilizumab were further evaluated for a severe outcome (encompassing both the use… Continue reading "(04 May 2020) Tocilizumab- reduced effects of Tocilizumab in hyperglycemic patients"

(02 May 2020) Hydroxychloroquine- slower viral clearance with HCQ use in COVID-19 patients

May 5, 2020

Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: A retrospective study https://doi.org/10.1101/2020.04.27.20082180 In a retrospective observational study at Cleveland Clinic Abu Dhabi assessment of the efficacy of HCQ w.r.t SARS-CoV-2 viral clearance… Continue reading "(02 May 2020) Hydroxychloroquine- slower viral clearance with HCQ use in COVID-19 patients"

(01 May 2020) Telmisartan- treating COVID-19 patients prior to development of ARDS

May 5, 2020

Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID‐19 https://doi.org/10.1002/ddr.21679 High levels of angiotensin II on the lung interstitium can promote apoptosis initiating an inflammatory process with release of proinflammatory cytokines, establishing a self‐powered cascade, leading eventually to ARDS. Telmisartan… Continue reading "(01 May 2020) Telmisartan- treating COVID-19 patients prior to development of ARDS"

(01 May 2020) Tocilizumab- reduced mortality in severe COVID 19 patients

May 5, 2020

Effective treatment of severe COVID-19 patients with tocilizumab https://doi.org/10.1073/pnas.2005615117 This is a retrospective study on tocilizumab, an IL6R inhibitor, in treatment of 21 patients with severe and critical COVID-19. Within 5 days after tocilizumab, 15 of the 20 patients (75.0%)… Continue reading "(01 May 2020) Tocilizumab- reduced mortality in severe COVID 19 patients"

(01 May 2020) Hydroxychloroquine – decreased mortality in critically ill COVID patients

May 3, 2020

Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19 https://doi.org/10.1101/2020.04.27.20073379 Data from a retrospective study on 568 critically ill COVID-19 patients suggests that hydroxychloroquine could be used to treat critically ill patients with COVID-19 which… Continue reading "(01 May 2020) Hydroxychloroquine – decreased mortality in critically ill COVID patients"

(30 April 2020)Favipiravir – early viral clearance contributed to the improvement of chest imaging on Day 14

May 3, 2020

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study https://doi.org/10.1016/j.eng.2020.03.007 In this open-label comparative controlled study of patients with COVID-19, those treated with Favipiravir (FPV) appeared to have faster viral clearance and better chest imaging change on day 14… Continue reading "(30 April 2020)Favipiravir – early viral clearance contributed to the improvement of chest imaging on Day 14"

Month: May 2020